Gilead Sciences, Inc.

GIS.DE

GIS.DEGilead Sciences, Inc. DE flag

Deutsche Börse

93.67

EUR

-0.14

(-0.15%)

4.06EPS

23.07P/E

116.52BMarket Cap

Aug 07Next Earn

ISIN

US3755581036

Return %

Stock

S&P500

41.92

10.14

53.81

62.89

41.09

93.94

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	6.41	7.33	16.35	22.29	22.7	19.97	17.05	17.68	19.64	21.74	21.74	21.73	23.06	23.04
Basic EPS, GAAP	1.71	2.01	7.95	12.37	10.08	3.54	4.2	4.24	0.1	4.96	3.66	4.54	0.38	4.78
Free Cash Flow per Basic Share	2.11	2.03	8.42	14.52	12.73	9.1	6.47	7.2	6.5	9.06	7.23	6.42	8.68	8.23
Dividend per Share	- -	- -	- -	1.28	1.83	2.09	2.29	2.54	2.74	2.87	2.96	3.05	3.14	3.16
Book Value per Share	2.45	4	8.37	12.3	13.56	14.55	14.66	15.27	11.44	13	12.5	13.06	9.22	8.77
Tangible Book Value per Share	-2.15	-0.87	2.35	5.26	6.89	-0.58	1.29	3.74	-18.31	-16.5	-12.75	-9.63	-7.23	-6.89
Basic Weighted Avg Shares	1,515	1,529	1,522	1,464	1,339	1,307	1,298	1,270	1,257	1,256	1,255	1,248	1,247	1,247
Sales/Revenue/Turnover	9,702	11,202	24,890	32,639	30,390	26,107	22,127	22,449	24,689	27,305	27,281	27,116	28,754	28,734
Operating Margin (%)	41.33	40.39	61.33	68	58.02	54.1	42.02	41.6	40.21	39.76	40.23	32.49	36.53	37.43
Depreciation Expense	278	345	1,050	1,098	1,158	1,286	1,429	1,404	1,480	2,050	2,103	2,693	2,767	2,773
Net Income, GAAP	2,592	3,075	12,101	18,108	13,501	4,628	5,455	5,386	123	6,225	4,592	5,665	480	5,965
Effective Tax Rate (%)	28.74	27.35	18.83	16.4	21.11	65.67	29.99	- -	94.67	25.09	21.47	18.18	30.58	12.6
Profit Margin (%)	26.72	27.45	48.62	55.48	44.43	17.73	24.65	23.99	0.5	22.8	16.83	20.89	1.67	20.76
Working Capital	1,918	590	11,953	14,872	10,370	20,188	25,231	20,537	4,599	3,162	3,205	4,805	7,169	4,558
LT Debt	7,055	3,939	11,921	21,073	26,346	30,795	24,574	22,094	28,645	25,179	22,957	23,189	24,896	22,146
Total Equity	9,544	11,745	15,819	19,113	19,363	20,501	21,534	22,650	18,221	21,064	21,209	22,749	19,246	19,078
Return on Invested Capital (%)	17.96	18.43	53.74	54.43	32.6	9.75	12.67	- -	1.1	16.76	18.29	15.2	15.38	21.82
Return on Capital (%)	26.44	26.22	64.57	56.48	33.35	10.24	12.52	- -	0.47	15.76	12.76	15.81	2.92	19.07
Return on Common Equity (%)	94.53	62.66	128.45	117.83	74.68	24.9	28.68	28.04	0.73	40.54	28.69	35.41	3.45	55.26

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	2.23%	5.19%	6.04%
Net Income, GAAP	474.4%	953.77%	-91.53%
Free Cash Flow	2.72%	6.38%	35.25%
Total Cash Common Dividend	- -	4%	2.86%
Total Equity	2.68%	-2.28%	-15.4%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Daniel P. O'Day
Full Time Employees: 17,600
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: 333 Lakeside Drive Foster City CA United States of America 94404
IPO Date: Jan 3, 2000
Website: gilead.com
Similar Companies: Boai NKY Medical Holdings Ltd. (300109.SZ)
Psyence Group Inc. (PSYG.CN)
Biogen Inc. (BIIB)
Orion Oyj (ORINF)
Daewoong Co., Ltd. (003090.KS)
Pfizer Limited (PFIZER.NS)
Business: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

	Sep'24	Dec'24	Mar'25
ST Debt	1,812	1,815	2,806
LT Borrowings	21,437	24,896	22,146
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,246	1,246	1,245
Market Capitalization	103,434	116,242	139,687

	Sep'24	Dec'24	Mar'25
Total Current Assets	14,779	19,173	16,901
Accounts Receivable, Net	4,587	4,420	4,388
Cash, Cash Equivalents & STI	5,037	11,568	7,926
Inventories	1,869	1,710	1,759
Total Current Liabilities	11,724	12,004	12,343
Payables & Accruals	6,552	6,371	4,922
ST Debt	1,812	1,815	2,806
Deferred Revenue	- -	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	6.41	7.33	16.35	22.29	22.7	19.97	17.05	17.68	19.64	21.74	21.74	21.73	23.06	23.04
Basic EPS, GAAP	1.71	2.01	7.95	12.37	10.08	3.54	4.2	4.24	0.1	4.96	3.66	4.54	0.38	4.78
Free Cash Flow per Basic Share	2.11	2.03	8.42	14.52	12.73	9.1	6.47	7.2	6.5	9.06	7.23	6.42	8.68	8.23
Dividend per Share	- -	- -	- -	1.28	1.83	2.09	2.29	2.54	2.74	2.87	2.96	3.05	3.14	3.16
Book Value per Share	2.45	4	8.37	12.3	13.56	14.55	14.66	15.27	11.44	13	12.5	13.06	9.22	8.77
Tangible Book Value per Share	-2.15	-0.87	2.35	5.26	6.89	-0.58	1.29	3.74	-18.31	-16.5	-12.75	-9.63	-7.23	-6.89
Basic Weighted Avg Shares	1,515	1,529	1,522	1,464	1,339	1,307	1,298	1,270	1,257	1,256	1,255	1,248	1,247	1,247
Sales/Revenue/Turnover	9,702	11,202	24,890	32,639	30,390	26,107	22,127	22,449	24,689	27,305	27,281	27,116	28,754	28,734
Operating Margin (%)	41.33	40.39	61.33	68	58.02	54.1	42.02	41.6	40.21	39.76	40.23	32.49	36.53	37.43
Depreciation Expense	278	345	1,050	1,098	1,158	1,286	1,429	1,404	1,480	2,050	2,103	2,693	2,767	2,773
Net Income, GAAP	2,592	3,075	12,101	18,108	13,501	4,628	5,455	5,386	123	6,225	4,592	5,665	480	5,965
Effective Tax Rate (%)	28.74	27.35	18.83	16.4	21.11	65.67	29.99	- -	94.67	25.09	21.47	18.18	30.58	12.6
Profit Margin (%)	26.72	27.45	48.62	55.48	44.43	17.73	24.65	23.99	0.5	22.8	16.83	20.89	1.67	20.76
Working Capital	1,918	590	11,953	14,872	10,370	20,188	25,231	20,537	4,599	3,162	3,205	4,805	7,169	4,558
LT Debt	7,055	3,939	11,921	21,073	26,346	30,795	24,574	22,094	28,645	25,179	22,957	23,189	24,896	22,146
Total Equity	9,544	11,745	15,819	19,113	19,363	20,501	21,534	22,650	18,221	21,064	21,209	22,749	19,246	19,078
Return on Invested Capital (%)	17.96	18.43	53.74	54.43	32.6	9.75	12.67	- -	1.1	16.76	18.29	15.2	15.38	21.82
Return on Capital (%)	26.44	26.22	64.57	56.48	33.35	10.24	12.52	- -	0.47	15.76	12.76	15.81	2.92	19.07
Return on Common Equity (%)	94.53	62.66	128.45	117.83	74.68	24.9	28.68	28.04	0.73	40.54	28.69	35.41	3.45	55.26

Year	Q1	Q2	Q3	Q4	FY
2023	0.81	0.84	1.75	1.15	4.54
2024	-3.34	1.29	1	1.43	0.38
2025	1.06	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	0.78	0.76	0.76	0.76	3.05
2024	0.79	0.78	0.79	0.78	3.14
2025	0.81	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	6,352	6,599	7,050	7,114	27,116
2024	6,686	6,953	7,545	7,569	28,754
2025	6,667	- -	- -	- -	- -

Gilead Sciences, Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year